Is Coherus Oncology, Inc. CHRS stock Halal to invest in?

No, as of September 2026, Coherus Oncology, Inc. stock (CHRS) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening Halal stocks. To qualify as Halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. Coherus Oncology, Inc. currently does not meet the threshold for the interest-bearing investments screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of Coherus Oncology, Inc. and discover Shariah compliant alternatives among the Halal stocks in the Tabadulat app.

How often is Coherus Oncology, Inc. CHRS reviewed for Shariah compliance?

Tabadulat reviews Coherus Oncology, Inc. CHRS for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Coherus Oncology, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Non Permissible Income criteria?

Yes, as of September 2026, Coherus Oncology, Inc. stock (CHRS) passes the AAOIFI non-permissible income screen. AAOIFI permits a small tolerance because large companies rarely avoid incidental impermissible income entirely, most often interest on cash balances. The ceiling is 5% of total revenue, and Coherus Oncology, Inc. sits inside it in the latest screening. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Interest Bearing Investments criteria?

No, as of September 2026, Coherus Oncology, Inc. stock (CHRS) does not pass the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. Coherus Oncology, Inc.'s interest-bearing investments currently exceed this 30% limit, meaning too large a share of the company's value derives from Riba-based instruments for the stock to qualify as Halal on this criterion. The ratio moves with both the balance sheet and the share price, and is reassessed monthly.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Coherus Oncology, Inc. stock (CHRS) passes the AAOIFI interest-bearing debt screen. Each month Tabadulat measures Coherus Oncology, Inc.'s interest-accruing borrowings against AAOIFI's 30% market capitalisation cap. The current screening shows the company within the limit, so the debt screen passes. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Coherus Oncology, Inc. CHRS stock?

Coherus Oncology, Inc. (CHRS) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (Tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a Halal investment. If Coherus Oncology, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Coherus Oncology, Inc. stock (CHRS) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Coherus Oncology, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Coherus Oncology (CHRS) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

As of the September 2026 screening, Coherus Oncology, Inc. (CHRS) does not meet the AAOIFI Shariah Standard No. 21 threshold for the interest-bearing investments screen, so the stock is not currently classified as Shariah compliant. It is re-screened every month and can regain compliance if its financial structure changes.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

228

Website:

https://www.coherus.com

Market cap:

$219M

P/E ratio:

3.1

Dividend yield:

52-week range:

$1.09 - $2.62

Data as of:

3 September 2026

Screening history:

September 2026: FAIL

Coherus Oncology is a biotechnology company focused on developing, manufacturing, and commercializing biosimilar products. Biosimilars are highly similar to existing, approved biological medicines with no clinically meaningful differences in terms of safety or efficacy. Coherus Biosciences aims to provide more accessible biological therapeutics in key therapeutic areas such as oncology, ophthalmology, and immunology. By doing so, the company addresses the need for more cost-effective treatment options and aims to contribute to the sustainability of healthcare systems globally. For Muslim investors, though, the most pressing question is simpler: is Coherus Oncology a Halal investment?

Is Coherus Oncology Shariah compliant?

Technology companies rarely fail AAOIFI screening on what they sell. Software, hardware and digital services are permissible business activities, so for a company like Coherus Oncology the Shariah question moves to the balance sheet: how much of its market value sits in interest bearing debt, how much of its cash earns Riba in conventional deposits, and whether incidental income from impermissible sources creeps past 5% of revenue. These are exactly the ratios AAOIFI Shariah Standard No. 21 polices, and they move every month with the share price.

Does Coherus Oncology pass the business activity test?

The activity screen is only part of the picture this month: Coherus Oncology currently fails the interest-bearing investments screen, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Coherus Oncology's income Halal?

Yes, within AAOIFI's tolerance. Coherus Oncology's income from non-permissible sources stays below 5% of revenue in the September 2026 screening.

Does Coherus Oncology meet AAOIFI's debt and investment ratio requirements?

Not in full. Interest bearing investments currently exceed the 30% cap, while the other ratio stays within it. One breach is enough to fail the screening; the ratios are reassessed monthly under our Shariah Supervisory Board.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.